Loading organizations...
Key people at Compugen.
Compugen is an enterprise IT solutions provider delivering hardware, software, network infrastructure, and sustainable IT asset disposition services, based in Richmond Hill, Ontario. Operating as Canada's largest privately owned IT solutions firm, the company generates approximately $625.6 million in annual revenue and employs a workforce of roughly 1,800 people across its North American corporate offices. To expand its capabilities in wireless technology, secure endpoint management, and Indigenous-led IT services, the organization acquired Valet Wireless, NPC, and FoxWise in 2020. The firm previously combined operations with Metafore to consolidate its market position and established its first United States facility in Houston, Texas, to support cross-border enterprise customers. The executive team includes Chief Sales Officer Jeremy Erlick and Chief Customer Officer Stéphan Wener, who oversee ongoing commercial growth initiatives. Compugen was founded in 1981 by Harry Zarek.
Compugen Ltd (CGEN) is a clinical-stage cancer immunotherapy company pioneering computational target discovery to identify novel drug targets and biological pathways for cancer treatments.[2] Headquartered in Holon, Israel (with investor relations in Cambridge, UK), it leverages a predictive computational discovery platform to develop therapeutics that extend immuno-oncology to broader patient populations, focusing on shifting the cancer treatment landscape.[2]
Unlike a traditional chemicals & plastics firm (an outdated classification from some databases), Compugen operates in biotechnology, specifically drug discovery and development.[1][2] It serves oncology patients and partners by addressing unmet needs in immunotherapy, with growth tied to clinical pipeline advancements in novel targets.[2]
Compugen was founded in 1993 in Israel as a computational biology pioneer, evolving from early genomics tools to a dedicated cancer immunotherapy focus after recognizing immuno-oncology's transformative potential.[2] The company transitioned into a clinical-stage biopharma player, building a proprietary platform for target discovery that has driven its pipeline in novel biological pathways.[2]
Key milestones include public listing on NASDAQ (CGEN) and relocating headquarters to Holon, Israel, while expanding global investor outreach.[1][2] This evolution reflects founders' backgrounds in computational science applied to drug discovery, humanizing its shift from tech origins to life-saving cancer therapies.[2]
Compugen stands out in biotech through these strengths:
These elements provide a tech-driven edge over conventional biopharma, emphasizing speed and precision in target identification.[2]
Compugen rides the AI-driven drug discovery wave, intersecting computational biology with booming immuno-oncology amid surging demand for personalized cancer therapies.[2] Timing aligns with post-2020 immuno-oncology expansions (e.g., checkpoint inhibitors), where market forces like aging populations and biotech funding favor novel targets over saturated ones.[2]
It influences the ecosystem by validating computational platforms as scalable alternatives to high-cost trials, inspiring hybrid AI-biotech models and partnerships that accelerate oncology innovation.[2] In Israel's "Startup Nation" biotech hub, Compugen exemplifies how tech heritage fuels global health impacts.[1][2]
Compugen's trajectory hinges on clinical trial readouts for its immunotherapy candidates, potentially unlocking partnerships or approvals amid AI-biotech convergence.[2] Trends like multimodal AI for target validation and combination therapies will shape its path, amplifying influence if pipeline successes materialize.
As a computational pioneer from code to potential cures, Compugen could redefine accessible immuno-oncology, extending its high-level mission to transform cancer care for millions.[2]
Key people at Compugen.
